The present study, for the first time, provides a critical reference point for further studies to unravel the molecular mechanisms involved in the selective vulnerability/resistance of particular brain regions to tau pathology in AD and related neurodegenerative disorders. The gene discussed is MAPT; the disease is Alzheimer disease.